BioCryst Pharmaceuticals Inc. has granted 24 newly-hired employees stock options to purchase a total of 251,150 shares and restricted stock units (RSUs) for a total of 368,550 shares of company common stock. The stock options have an exercise price of $6.63 per share, matching the closing price on the grant date of February 2, 2026. Both the options and RSUs will vest in four equal annual installments starting one year from the grant date, contingent on continued employment. Each stock option carries a 10-year term and is subject to the company’s Inducement Equity Incentive Plan and related agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648921-en) on February 05, 2026, and is solely responsible for the information contained therein.